Tilomisole
Tilomisole (Wy 18251) is a benzimidazothiazole experimental agent with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation[1][2].
Product Specifications
CAS Number
58433-11-7
Product Name Alternative
Wy 18251
UNSPSC
12352005
Target
COX
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tilomisole.html
Solubility
10 mM in DMSO
Smiles
O=C(CC1=C(C2=CC=C(Cl)C=C2)N3C4=C(C=CC=C4)N=C3S1)O
Molecular Formula
C17H11ClN2O2S
Molecular Weight
342.80
References & Citations
[1]Dillman RO, et al. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients. Mol Biother. 1992;4 (1) :10-14.|[2]Darwish SA, et al. New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies [published online ahead of print, 2022 Jan 29]. Bioorg Chem. 2022;120:105644.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
